An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)
NCT01283074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107
Last updated 2016-11-02
Summary
This observational, multi-center, open-label study will evaluate the prognostic factors of long-term-response and the safety of Pegasys (peginterferon alfa-2a) in patients with HbeAg-negative chronic hepatitis B. Data will be collected for 96 weeks.
Conditions
- Hepatitis B, Chronic
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-05-31
- Primary Completion
- 2012-11-30
- Completion
- 2012-11-30
Countries
- Greece
Study Locations
More Related Trials
-
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
NCT01730508 ·Status: COMPLETED
-
An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B
NCT01787279 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).
NCT00435825 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam
NCT01886300 ·Status: TERMINATED
-
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study
NCT02201407 ·Status: COMPLETED
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
NCT01519921 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
NCT02791269 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
NCT02570191 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
NCT02604823 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
NCT01086085 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
NCT00487747 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy
NCT02068365 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
NCT00922207 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
NCT01179594 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression
NCT01706575 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
NCT00940485 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
NCT00436163 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
NCT01519960 ·Status: COMPLETED ·Phase: PHASE3
-
Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253
NCT01237496 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253
NCT01697501 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment
NCT00226382 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
NCT01679834 ·Status: COMPLETED
-
A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265
NCT01645969 ·Status: COMPLETED
-
Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
NCT02822547 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
NCT00614471 ·Status: COMPLETED ·Phase: PHASE4